Sacubitril/Valsartan Demonstrates Potential in Reducing Anthracycline-Induced Cardiotoxicity: Insights from the SARAH Trial

ARNI Reduces Cardiotoxicity in Cancer Patients

A randomized controlled trial (SARAH) suggests sacubitril/valsartan (ARNI) can protect against cardiotoxicity caused by anthracycline chemotherapy in high-risk cancer patients. This is the first trial to demonstrate ARNI's potential in this setting.

Role of ARNI in Cardio-Oncology

Sacubitril/valsartan, FDA-approved for heart failure, shows promise as a cardioprotective agent. Anthracyclines, while effective in cancer treatment, carry a significant risk of dose-dependent cardiotoxicity.

Trial Design and Rationale

Researchers targeted high-risk patients with evidence of myocardial injury from chemotherapy. They chose ARNI based on its established role in heart failure and supportive animal model data.

Study Overview

The SARAH trial enrolled 114 high-risk cancer patients undergoing anthracycline chemotherapy. Patients were randomized to receive sacubitril/valsartan or placebo over 24 weeks.

Key Findings

The primary endpoint, a ≥15% reduction in global longitudinal strain (GLS), was 77% lower in the ARNI group (7.1% vs. 25%). GLS improved in the treatment group but worsened in the placebo group.

Additional Outcomes

Fewer ARNI patients had LVEF < 50% or GLS < 18%. Clinical events were rare and similar across groups, though ARNI patients experienced more hypotension and higher potassium levels.

Next Steps in Research

Experts emphasize validating SARAH’s findings in larger populations. Longer-term trials, like PRADA II, will provide further insight into ARNI's sustainability and impact on outcomes.

Cost Considerations

While ARNI offers significant benefits, its high cost has limited accessibility. Efforts are underway to negotiate lower prices to increase its uptake.

Mechanism and Efficacy

Sacubitril/valsartan's dual mechanism enhances the natriuretic peptide system while mitigating neprilysin's negative effects. Animal studies indicate that sacubitril/valsartan outperforms valsartan alone in cardioprotection.

---

Take-Home Points

1. ARNI shows promise in reducing cardiotoxicity in high-risk cancer patients receiving anthracycline chemotherapy.
2. Primary outcome: ARNI significantly reduced GLS decline compared to placebo.
3. Secondary benefits: Fewer patients experienced critical declines in LVEF and GLS.
4. Challenges: Cost remains a barrier; further trials are needed for validation.
5. Next steps: Research should focus on long-term sustainability and broader population studies.

Learn More